Inflarx's gohibic (vilobelimab) selected for first barda-sponsored clinical trial to evaluate novel host-directed therapeutics for acute respiratory distress syndrome (ards)

Jena, germany, june 24, 2024 (globe newswire) -- inflarx n.v. (nasdaq: ifrx), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that gohibic (vilobelimab) has been selected by the biomedical advanced research and development authority (barda), part of the administration for strategic preparedness and response within the u.s. department of health and human services, as one of three investigational therapies to be assessed in a phase 2 clinical platform study exploring potential new options for the treatment of acute respiratory distress syndrome (ards).
ARDS Ratings Summary
ARDS Quant Ranking